Key Points Nuvation Bio enrolled the first patient in a late-stage study of Ibtrozi. The bigger story, though, was a Wall Street analyst's initiation of coverage on the stock. 10 stocks we like better than Nuvation Bio › Shares of Nuvation Bio (NYSE: NUVB) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday. The big jump came after two positive developments for the cancer-focused drugmaker. Nuvation Bio announced on Tuesday morning that it has enrolled the first patient in its phase 3 cl ...